Community Healthcare Trust vs. Sabra Health Care REIT: Which Real Estate Stock Is a Better Buy in 2026?

Sabra Health Care REIT generated FY 2025 revenue of $774.6 million and net income of $155.6 million, with a 20.1% net margin and a 6.41% dividend yield, making it the article’s preferred 2026 pick over Community Healthcare Trust. Community Healthcare Trust posted FY 2025 revenue of $121.2 million, net income of $5.1 million, and a 4.2% net margin, while both stocks are framed as rate-sensitive healthcare REITs with differing risk/reward profiles. Valuation is mixed: Sabra trades at 27.4x forward P/E versus CHCT at 37.2x, but CHCT has the lower price-to-sales ratio at 4.1x versus 6.0x.

Analysis

SBRA is the cleaner way to express the aging-demographics trade because it monetizes the part of the care continuum with the least substitutability and the most pricing leverage when occupancy tightens. The market is still discounting a long-duration rate headwind, but that is exactly why the setup is interesting: once financing expectations stabilize, the stock can re-rate faster than its fundamentals because the biggest overhang is multiple compression rather than cash-flow deterioration.

CHCT is the lower-beta operator structurally, but it is more exposed to idiosyncratic tenant and regional shocks, which means the equity behaves like a smaller-cap credit story disguised as a REIT. The subscale balance sheet and thinner liquidity make it more vulnerable if one or two tenants hit reimbursement or balance-sheet pressure; that risk compounds over months, not days, and is harder for the market to underwrite versus SBRA's diversified earnings base.

The contrarian angle is that the crowd is likely overpaying for the “safe outpatient” narrative while underestimating the reflexivity in SBRA: if ATMs slow and rates drift lower, dividend stability plus earnings leverage can pull in income capital that is currently sitting on the sidelines. By contrast, CHCT’s valuation discount may simply reflect a structurally lower ceiling on growth and a higher probability that any single operational miss forces a reset in payout expectations.

The key catalyst window is the next 1-3 quarters: watch for rate relief, leasing spreads, and whether managed senior housing margins keep improving enough to offset labor inflation. If that data confirms stabilization, SBRA has the higher upside beta; if rates stay sticky and cap rates back up, both names can underperform, but CHCT should compress first because of weaker liquidity and lower earnings quality.

Key Decisions for Investors

• Long SBRA / short CHCT as a 6-12 month relative-value pair: thesis is that SBRA's earnings leverage and dividend support will outperform CHCT's tenant-concentration risk if rates stabilize.
• Buy SBRA on weakness for an income-plus-re-rating trade with a 3-6 month horizon; target a move driven by reduced financing fears, but cut risk if long rates re-accelerate or dilution risk returns.
• Avoid initiating a fresh long in CHCT until there is evidence of tenant credit stabilization; the risk/reward is poor because one lease failure can overwhelm modest NOI growth.
• For options-oriented accounts, consider a medium-dated bullish call spread on SBRA rather than stock if you want rate-duration upside with defined downside.
• If 10-year yields break higher again, hedge REIT exposure by trimming both names, but reduce CHCT first because it should be the faster de-rate under stress.